search
Back to results

XG005 for Pain Control in Subjects Undergoing Bunionectomy

Primary Purpose

Acute Pain

Status
Recruiting
Phase
Phase 2
Locations
United States
Study Type
Interventional
Intervention
XG005 tablet
Placebo tablet
Sponsored by
Xgene Pharmaceutical Group
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional prevention trial for Acute Pain

Eligibility Criteria

18 Years - 80 Years (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Main inclusion criteria: Scheduled to undergo unilateral first metatarsal bunionectomy Have negative urine drug screen Non-pregnant, non-lactating Main exclusion criteria: Medical condition or history that in the investigator's opinion could adversely impact the subject's participation or safety Use of disallowed medications (e.g. pain medication, CNS active drugs such as benzodiazepines, tricyclic antidepressants, Serotonin, and norepinephrine reuptake inhibitors (SNRIs), selective serotonin reuptake inhibitors (SSRIs), or any other serotonergic medications, parenteral or oral corticosteroids) Antihypertensive agent or diabetic regimen at a dose that has not been stable for at least 30 days Digoxin, warfarin lithium, theophylline preparations, aminoglycosides, and all antiarrhythmics Monoamine oxidase inhibitors (MAOIs) Positive HbsAg and/or anti-HBc but negative anti-HBs HIV infection History of illicit drug use History of opioid dependence History of NSAID-induced bronchospasm or presence of nasal polyps, history of asthma or chronic rhinitis Significant history of allergic reactions or known intolerance to naproxen, pregabalin or any gabapentinoid, or to any rescue medication used in the study, or any medication used in the surgical and anesthetic protocol. Presence of severe depression as indicated by Patient Health Questionnaire (PHQ 9) total score of ≥20 or item 9 score >0 Presence of severe anxiety as indicated by General Anxiety Disorder (GAD-7) score of ≥15 Presence of history of suicidal behavior or ideation as indicated by the C-SSRS

Sites / Locations

  • Midwest Clinical Research CenterRecruiting
  • First Surgical HospitalRecruiting
  • Legent Orthopedic Hospital
  • Memorial Hermann Village
  • Endeavor Clinical TrialsRecruiting

Arms of the Study

Arm 1

Arm 2

Arm 3

Arm Type

Experimental

Experimental

Placebo Comparator

Arm Label

high dose

low dose

placebo

Arm Description

XG005 1250 mg Q12 hours

XG005 750 mg Q12 hours

placebo Q12 hours

Outcomes

Primary Outcome Measures

Summed pain intensity from end of surgery to 48 hours post-surgery
Pain assessments via a standard 11-point NPRS at the various time points post-end of surgery

Secondary Outcome Measures

Total tramadol rescue medication consumption
Tramadol 50 mg, PRN
Time to first use of rescue medication from end of surgery
Acetaminophen 1g, PRN
Patient Global Assessment (PGA) at 48 hours
PGA of pain control using a 5 point scale at the following time points post-surgery
Cumulative Nausea (NNRS) assessment scores through 24 hours
NNRS assessment scores at various time points
TEAEs
First dose of study drug to 30 days after the last dose of study drug
Continuous Pulse Oximetry
oxygen saturation (Sp02) will be recorded every 12 hours post-end of surgery.

Full Information

First Posted
August 18, 2023
Last Updated
August 24, 2023
Sponsor
Xgene Pharmaceutical Group
search

1. Study Identification

Unique Protocol Identification Number
NCT06017999
Brief Title
XG005 for Pain Control in Subjects Undergoing Bunionectomy
Official Title
A Randomized, Double-Blind, Placebo Controlled Trial to Evaluate the Safety and Efficacy of XG005 Tablets in Subjects Undergoing Bunionectomy
Study Type
Interventional

2. Study Status

Record Verification Date
August 2023
Overall Recruitment Status
Recruiting
Study Start Date
August 8, 2023 (Actual)
Primary Completion Date
May 31, 2024 (Anticipated)
Study Completion Date
August 30, 2024 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Xgene Pharmaceutical Group

4. Oversight

Studies a U.S. FDA-regulated Drug Product
Yes
Studies a U.S. FDA-regulated Device Product
No

5. Study Description

Brief Summary
This study will evaluate the safety, efficacy, and PK of low dose (750 mg) and high-dose (1250 mg) XG005 oral tablets compared with placebo in subjects undergoing bunionectomy. Subjects will be confined in the clinic from check-in through 72 hours post-surgery to monitor subject safety.
Detailed Description
This is a multi-center, randomized, double-blind, parallel-group, placebo-controlled study. Eligible subjects will be randomized in a 1:1:1 ratio to receive either 750 mg XG005, 1250 mg XG005, or placebo, twice a day, post bunionectomy surgery in domiciled clinic. Subjects and all study staff performing study assessments will be blinded to treatment allocation. Subjects will be discharged at a reasonable hour of the day after the end of the 72-hour treatment period.There will be a Follow-up Visit on Day 15.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Acute Pain

7. Study Design

Primary Purpose
Prevention
Study Phase
Phase 2, Phase 3
Interventional Study Model
Parallel Assignment
Masking
ParticipantCare ProviderInvestigatorOutcomes Assessor
Allocation
Randomized
Enrollment
450 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
high dose
Arm Type
Experimental
Arm Description
XG005 1250 mg Q12 hours
Arm Title
low dose
Arm Type
Experimental
Arm Description
XG005 750 mg Q12 hours
Arm Title
placebo
Arm Type
Placebo Comparator
Arm Description
placebo Q12 hours
Intervention Type
Drug
Intervention Name(s)
XG005 tablet
Intervention Description
Subjects will receive XG005 prior to surgery and every 12 hours for 72 hours.
Intervention Type
Drug
Intervention Name(s)
Placebo tablet
Intervention Description
Subjects will receive placebo prior to surgery and every 12 hours for 72 hours.
Primary Outcome Measure Information:
Title
Summed pain intensity from end of surgery to 48 hours post-surgery
Description
Pain assessments via a standard 11-point NPRS at the various time points post-end of surgery
Time Frame
0 to 72 hours post-surgery
Secondary Outcome Measure Information:
Title
Total tramadol rescue medication consumption
Description
Tramadol 50 mg, PRN
Time Frame
0 to 72 hours post-surgery
Title
Time to first use of rescue medication from end of surgery
Description
Acetaminophen 1g, PRN
Time Frame
0 to 72 hours post-surgery
Title
Patient Global Assessment (PGA) at 48 hours
Description
PGA of pain control using a 5 point scale at the following time points post-surgery
Time Frame
0 to 72 hours post-surgery
Title
Cumulative Nausea (NNRS) assessment scores through 24 hours
Description
NNRS assessment scores at various time points
Time Frame
0 to 72 hours post-surgery
Title
TEAEs
Description
First dose of study drug to 30 days after the last dose of study drug
Time Frame
Day 1 to Day 30
Title
Continuous Pulse Oximetry
Description
oxygen saturation (Sp02) will be recorded every 12 hours post-end of surgery.
Time Frame
0 to 72 hours post-surgery

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
80 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Main inclusion criteria: Scheduled to undergo unilateral first metatarsal bunionectomy Have negative urine drug screen Non-pregnant, non-lactating Main exclusion criteria: Medical condition or history that in the investigator's opinion could adversely impact the subject's participation or safety Use of disallowed medications (e.g. pain medication, CNS active drugs such as benzodiazepines, tricyclic antidepressants, Serotonin, and norepinephrine reuptake inhibitors (SNRIs), selective serotonin reuptake inhibitors (SSRIs), or any other serotonergic medications, parenteral or oral corticosteroids) Antihypertensive agent or diabetic regimen at a dose that has not been stable for at least 30 days Digoxin, warfarin lithium, theophylline preparations, aminoglycosides, and all antiarrhythmics Monoamine oxidase inhibitors (MAOIs) Positive HbsAg and/or anti-HBc but negative anti-HBs HIV infection History of illicit drug use History of opioid dependence History of NSAID-induced bronchospasm or presence of nasal polyps, history of asthma or chronic rhinitis Significant history of allergic reactions or known intolerance to naproxen, pregabalin or any gabapentinoid, or to any rescue medication used in the study, or any medication used in the surgical and anesthetic protocol. Presence of severe depression as indicated by Patient Health Questionnaire (PHQ 9) total score of ≥20 or item 9 score >0 Presence of severe anxiety as indicated by General Anxiety Disorder (GAD-7) score of ≥15 Presence of history of suicidal behavior or ideation as indicated by the C-SSRS
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Joey Chang
Phone
312-468-5090
Email
joey.chang@xgenepharm.com
Facility Information:
Facility Name
Midwest Clinical Research Center
City
Dayton
State/Province
Ohio
ZIP/Postal Code
45417
Country
United States
Individual Site Status
Recruiting
Facility Name
First Surgical Hospital
City
Bellaire
State/Province
Texas
ZIP/Postal Code
77401
Country
United States
Individual Site Status
Recruiting
Facility Name
Legent Orthopedic Hospital
City
Carrollton
State/Province
Texas
ZIP/Postal Code
75006
Country
United States
Individual Site Status
Not yet recruiting
Facility Name
Memorial Hermann Village
City
Houston
State/Province
Texas
ZIP/Postal Code
77043
Country
United States
Individual Site Status
Not yet recruiting
Facility Name
Endeavor Clinical Trials
City
San Antonio
State/Province
Texas
ZIP/Postal Code
78229
Country
United States
Individual Site Status
Recruiting

12. IPD Sharing Statement

Learn more about this trial

XG005 for Pain Control in Subjects Undergoing Bunionectomy

We'll reach out to this number within 24 hrs